Balyasny Asset Management
RPTP

Balyasny Asset Management’s RAPTOR PHARMACEUTICAL CORP COM STK (DE) RPTP Stock Holding History

Balyasny Asset Management’s Portfolio RPTP Stock Details RPTP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-338,620
Closed -$1.82M – 1479
2016
Q2 		$1.82M Buy
338,620
+189,523
+127% +$972K 0.01% 693
2016
Q1 		$686K Sell
149,097
-1,255,744
-89% -$5.05M ﹤0.01% 821
2015
Q4 		$7.3M Buy
1,404,841
+808,536
+136% +$4.69M 0.05% 425
2015
Q3 		$3.61M Buy
+596,305
New +$7.31M 0.03% 571

Other funds holding RPTP

AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WIC
Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GLAM
Gardner Lewis Asset Management Chadds Ford, Pennsylvania $462M AUM 65.29% 1-Year Est. Return
OAC
OMERS Administration Corp Toronto, Ontario, Canada $15.6B AUM 24.73% 1-Year Est. Return

Balyasny Asset Management's RPTP Position: Q3 2016 in Review

Balyasny Asset Management sold out of RAPTOR PHARMACEUTICAL CORP COM STK (DE) (RPTP) in Q3 2016, closing a stake of 338,620 shares — an estimated $1.82M sold.

Balyasny Asset Management first reported a position in RPTP in Q3 2015 and held it in 4 quarters. The position peaked at $7.3M in Q4 2015. 111 funds tracked by Wall St. Rank hold RPTP as of Q3 2016.

  • Balyasny Asset Management reported no remaining RAPTOR PHARMACEUTICAL CORP COM STK (DE) position as of Q3 2016 after selling out during the quarter.
  • Balyasny Asset Management sold 338,620 RAPTOR PHARMACEUTICAL CORP COM STK (DE) shares in Q3 2016, an estimated $1.82M.
  • Balyasny Asset Management first reported a position in RAPTOR PHARMACEUTICAL CORP COM STK (DE) in Q3 2015 and held it in 4 quarters.
  • Balyasny Asset Management's RAPTOR PHARMACEUTICAL CORP COM STK (DE) position peaked at $7.3M in Q4 2015.
  • 111 funds tracked by Wall St. Rank held RAPTOR PHARMACEUTICAL CORP COM STK (DE) as of Q3 2016.

Based on Balyasny Asset Management's 13F filing for Q3 2016, filed 14 Nov 2016.